Update Overview – January 28th, 2021

Over the last several weeks, the Federal Drug Administration (FDA) has approved, or is in the process of approving,

Emergency Use Authorization (EUA) to Pfizer, Moderna, Eli Lilly and Regeneron Pharmaceuticals for their COVID-19

Vaccines or Infusion Treatment. The United States government, through Operation Warp Speed, has been working

since the onset of the pandemic to make one or more COVID-19 vaccines and infusions available as soon as possible.

Additional information can be found in the COVID-19 Vaccination Program Interim Playbook for Jurisdiction

Operations published by the Centers for Disease Control and Prevention (CDC) in October here: https://www.cdc.gov/

Initially, a limited supply of COVID-19 vaccines have been distributed to healthcare organizations. Vaccination efforts

will focus on those critical to the response. Those include first responders and frontline healthcare workers providing

direct care, as well as those at the highest risk for developing severe illness from COVID-19.

Phase 1a Distribution:

Healthcare personnel (paid and unpaid persons serving in healthcare setting who have the potential

for direct or indirect exposure to patients or infections materials)

Phase 1b Distribution:

Phase 1c Distribution:

Adults with high-risk medical conditions who possess risk factors for severe COVID-19 illness
Other essential workers

To review the CDC published recommendation on vaccine distribution, click HERE.

CMS has published Vaccination Provider Guidance to include a toolkit, enrollment and billing information,

and more. Click HERE to review.

Our Reports and Recommendations:

These materials are for general informational purposes only. These materials do not, and are not intended to, constitute

legal or compliance advice, and you should not act or refrain from acting based on any information provided

in these materials. Please consult with your own legal counsel or compliance professional regards specific legal or